Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma

Cancer

Volumn 88, Issue 6, 2000, Pages 1310-1316

  Reese, David M ^a   Corry, Michelle ^a   Small, Eric J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Floxuridine (FUDR); Interferon ; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA2B INTERFERON; FLOXURIDINE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DACRYOCYSTITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; COHORT STUDIES; DACRYOCYSTITIS; DIARRHEA; FATIGUE; FEMALE; FLOXURIDINE; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; WATER-ELECTROLYTE IMBALANCE;

EID: 0034653826     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1310::AID-CNCR6>3.0.CO;2-6     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-30.
2. Ritchie AW, Chishold GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390-400.
3. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 1995; 22:42-60.
4. Damascelli A, Marchiano A, Spreafico C, Lutman R, Salvetti M, Bonalumi MG, et al. Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 1990;66:237-42.
5. Conroy T, Geoffrois L, Guillemin F, Luporsi E, Krawkowski I, Spaeth D, et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 1993;72:2190-7.
6. Baiocchi C, Landonio G, Cacioppo C, Calgaro M, Cattaneo D, Ferrari M, et al. Continuous non-chronomodulated infusion of floxuridine in metastatic renal cell carcinoma. Tumori 1996;82:225-7.
7. Hrushesky WJ, von Roemling R, Lanning RM, Rabatin JT. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990;8:1504-13.
8. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, et al. A phase II study of constant infusion FUDR for the treatment of metastatic renal cell carcinoma. Cancer 1993;71:3601-4.
9. Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ. A phase I/II study of alternating constant infusion floxuridine with constant infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer 1994;73: 2803-7.
10. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80:1198-220.
11. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
12. Agarwala SS, Kirkwood JM. Interferons in the treatment of solid tumors. Oncology 1994;51:129-36.
13. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
14. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, et al. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am 1998;4:162-7.
15. Gleave ME, Elhilali M, Fradet Y, David I, Venner P, Saad F, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998;338: 1265-71.
16. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1271-8.
17. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 1995;13:174-7.
18. Chang S, Small EJ, Harney E, Frye J. Infusional floxuridine (FUDR)-based therapy for metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1998;17:263.
19. Falcone A, Cianci C, Pfanner E, Ricci S, Lencioni M, Brunetti I, et al. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. Ann Oncol 1996;7:601-5.
20. Soori GS, Schulof RS, Stark JJ, Wieman MC, Honeycutt PJ, Church CK, et al. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a National Biotherapy Study Group phase II study. Cancer Invest 1999;17:379-84.
21. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1992;10:275-81.
22. Fowler JE. Nephrectomy in metastatic renal cell carcinoma. Urol Clin North Am 1987;14:749-62.
23. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1987-1997. Cancer J Sci Am 1997;3:S73-8.
24. von Roemling R, Hrushesky WJ. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989;7:1710-9.